TenNor Therapeutics 1H FY26 loss narrows 17.81% to RMB 64.25 million

• TenNor Therapeutics posted a net loss of RMB 64.25 million for the six months ended June 30, narrowing from RMB 78.17 million.
• R&D expenses rose to RMB 31.32 million from RMB 26.32 million, due to NDA review and commercialization work for TNP-2198.
• Administrative costs climbed to RMB 32.01 million from RMB 18.61 million, driven by listing expenses and restricted-share grants.
• Cash and cash equivalents jumped to RMB 714.73 million at June 30 from RMB 183.77 million at Dec. 31 on IPO proceeds.
• Rifasutenizol entered NMPA supplementary review; rifaquizinone IA Phase Ib/IIa finished enrollment, while an NMPA-cleared Phase IIb was initiated.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tennor Therapeutics (Suzhou) Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12299912), on August 26, 2026, and is solely responsible for the information contained therein.